Boeing (BA) Tops Q3 EPS by 30c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Boeing (BA) Reports 3Q EPS Beat; Canaccord Genuity Reiterates Buy
October 22, 2015 10:27 AM EDTCanaccord Genuity reiterated a Buy rating and $165.00 price target on Boeing (NYSE: BA) following the company's 3Q15 earnings results. BA reported adjusted core EPS of $2.52 compared to the consensus estimates of $2.22.
Analyst Ken Herbert commented, "Boeing reported a better than expected Q3/15... More
RBC Capital Raises Price Target on Boeing (BA) Following 3Q15 EPS Beat
October 21, 2015 3:19 PM EDTRBC Capital reiterated a Sector Perform rating on Boeing (NYSE: BA), and raised the price target to $149.00 (from $145.00) following the company's 3Q15 earnings results. BA reported 'core' EPS of $2.52 coming in ahead of consensus at $2.21. Boeing defined 'core' EPS guidance was increased from... More
Wall St. declines; Valeant, healthcare weigh
October 21, 2015 7:08 AM EDTBy Caroline Valetkevitch
(Reuters) - U.S. stocks fell on Wednesday as a sharp drop in Valeant Pharmaceuticals hit the healthcare space, while the energy sector dropped along with oil prices.
Valeant Pharmaceuticals' (NYSE: VRX) U.S.-listed shares plunged to an intraday low of $88.50 on record volume after a short-seller accused the company of using specialty pharmacies to inflate its revenue.
The company denied the allegation, and later investor Bill Ackman said he increased his Valeant stake by about 2 million shares. The stock pared losses to end down 19.2 percent at $118.61,... More
